https://www.technologynetworks.com/genomics/news/mipomersen-phase-3-study-in-patients-with-heterozygous-familial-hypercholesterolemia-meets-primary-endpoint-201127
Study shows 28 percent reduction in LDL-cholesterol after 26 weeks of treatment reduction in high-risk patient population.
familial hypercholesterolemiamipomersenphasestudypatients